Twin Seed Tablet 40/5 mg
Telmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Mirae Bio Pharmaceutical Co., Ltd.
MFDS item code 201902593 · Approved 2019.04.25
This product's status changed to Expired on 2024.04.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not adequately controlled with amlodipine or telmisartan monotherapy
This medication is indicated for patients with essential hypertension. If blood pressure is not adequately controlled with amlodipine or telmisartan monotherapy, this medicine can be added to manage blood pressure effectively. By stabilizing blood pressure, the risk of complications related to hypertension, such as heart disease or stroke, can be reduced. This medication is used for the treatment of essential hypertension.
The recommended dose of this medicine is 1 tablet once daily, taken with water, regardless of meals. If possible, it is recommended that it be taken at the same time every day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not adequately controlled with the individual ingredients as described below, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. Patients taking telmisartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience (only applicable to this medicine 40/5 mg). ○ Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine dosage is recommended for elderly patients, but caution should be used when increasing the dose. (See section ‘3. Patients requiring caution when administering this medicine.’) In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
The safety and efficacy of this medicine have not been established in pediatric patients aged 18 years or younger; therefore, its use is not recommended.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should not be used by women who are pregnant or who may become pregnant. Patients with allergies to any of the ingredients in this medication or those with certain cardiovascular diseases, liver impairment, severe hypotension, or unstable conditions after acute myocardial infarction should not take this medication. Patients with liver dysfunction, biliary obstruction, gastrointestinal conditions, renal problems, and the elderly should exercise special caution when using this medication, and doses should be adjusted under the guidance of a physician. This medication can commonly cause side effects such as dizziness and leg swelling, and rarely may lead to serious side effects, so immediate medical consultation is required if any abnormal symptoms appear. The use of this medication should be avoided during pregnancy and, if pregnancy is confirmed, treatment should be discontinued as soon as possible and switched to a safer alternative. Since this medication lowers blood pressure, hypotension may occur, especially in patients with fluid depletion; conditions should be assessed before treatment starts. Caution is required when taking potassium supplements or foods high in potassium because of the increased risk of elevated potassium levels in the blood. Patients with renal impairment should have their kidney function and electrolyte levels regularly monitored while taking this medication. Patients with heart disease should be carefully monitored, as the use of this medication may increase the risk of angina pectoris or myocardial infarction. This medication may cause drowsiness or dizziness; therefore, caution should be exercised when driving or operating dangerous machinery. Drug interactions may occur when taking this medication with other drugs, so any other medications being taken should be disclosed to a physician or pharmacist. This medication is not recommended for children as its safety and effectiveness have not been sufficiently established in this population. In case of overdose, serious hypotension or cardiac function abnormalities may occur, requiring immediate medical attention for appropriate emergency treatment. Store this medicine out of reach of children, keeping it in its original packaging away from moisture and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that blocks light. To maintain the effectiveness of the medicine, store it at a temperature between 1°C and 30°C.
White and light gray biconvex oval double-coated tablet
30 tablets (10 tablets/PTP X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Mirae Bio Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.